Interventional Glaucoma

Melding ophthalmology and neurology

Mt. Sinai to introduce the miDOC system at the ASCRS annual meeting

A trio of ASCRS presentations collectively offer insight to surgeons, suggesting that glaucoma drops harm meibomian glands, while combining cataract surgery with MIGS can boost long-term IOP control.

Key regulatory filings, phase 3 readouts, and trial enrollments to watch through June 30.

The prospective, multicenter study enrolled 318 patients across 20 US sites.

See which ophthalmology surgery centers earn US News’ 2026 high-performing badge, where they cluster, and why complication rates drop 40%.

The BIM-IOL System consists of 2 non-bioerodible drug pads attached to the optic-haptic junction of a monofocal intraocular lens (IOL), which is implanted as part of routine cataract surgery.

Paula Anne Newman-Casey, MD, MS, explains the multifactorial needs and her decades-long research that resulted in the SEE program for glaucoma patients.

The 6-month Support, Educate, Empower (SEE) program was associated with a 20% improvement in glaucoma treatment adherence and reduced distress among adult patients.

Inder Paul Singh, MD, spoke alongside Mary Qiu, MD, and Danica J. Marrelli, OD, FAAO, AAODip, in a CE Spotlight Symposium at the conference.

Most patients do well on topical therapy, but innovation in IOP-lowering drops remains essential.

EnVision Summit insights spotlight complex glaucoma cases, MIGS pitfalls, and personalized surgery choices—preview the issues driving 2026 debates in Puerto Rico.

NYU Grossman’s Preeya Mehta, MD, and Jonathan S. Williams, MD, sit down with Mount Sinai’s Louis R. Pasquale, MD, to discuss long-term safety and efficacy data from a PreserFlo microshunt trial and the role of microshunts in glaucoma surgery.

AI is reshaping clinical practice in retinal imaging and workflow optimization, according to Priv.-Doz. Dr. med. Jan H. Terheyden, FEBO.

Commercial OCT maps five IPL sublayers; aging reduces contrast, hinting at earlier biomarkers for glaucoma and Alzheimer’s.

Glaukos noted under the updated labeling, physicians may now re-administer iDose TR more than once in patients who maintain a healthy cornea, as defined by corneal endothelial cell density parameters.

The trial will evaluate the safety and effectiveness of the company's titratable glaucoma therapy system, designed to optimize IOP reduction in patients undergoing glaucoma surgery.

Optometrists track 2026 breakthroughs in dry eye therapies, AI-powered screening and referrals, and genetics-driven glaucoma risk tools that reshape patient care.

James Tsai, MD, MBA, sheds light on what is in the offing for glaucoma specialists

James Tsai, MD, MBA, discusses his approaches given the wide diversity of patients in a major urban setting when awareness of glaucoma can range from highly educated patients to uninformed individuals.

Data estimates the prevalence of glaucoma currently is almost 50% higher than previously estimated and over 1.6 million individuals in the UK are estimated to have glaucoma by 2060.

The Bimatoprost Drug Pad-IOL System is intended for the lowering of intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT).

“Remarkable” results were reportedly obtained with hypotony with hydroxypropyl methylcellulose.

As Glaucoma Awareness Month highlights evolving practice, specialists describe how artificial intelligence, sustained drug delivery, laser therapy, and workflow integration are reshaping earlier, more individualized glaucoma care.